Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(92 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(170 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(86 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(78 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(27 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1375 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
FMP-API-1
CAS:<p>FMP-API-1 is an inhibitor of the A-kinase anchoring protein (AKAP)-PKA interaction. It binds to the allosteric site of the PKAR subunit, enhancing the activity of PKA and AQP2 in PKA knockout cell lines of the renal cortex collecting duct (mpkCCD cells). FMP-API-1 holds potential for studying nephrogenic diabetes insipidus (NDI).</p>Fórmula:C13H14N2O2Cor e Forma:SolidPeso molecular:230.262GENZ-882706
CAS:<p>GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor.</p>Fórmula:C26H25N5O3Pureza:98%Cor e Forma:SolidPeso molecular:455.51TRK-IN-26
CAS:<p>TRK-IN-26 (compound 12), a TRK inhibitor, holds potential for use in cancer research [1].</p>Fórmula:C30H22F2N6O4Cor e Forma:SolidPeso molecular:568.53EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Fórmula:C19H21N3O2SCor e Forma:SolidPeso molecular:355.45TrkC-IN-1
CAS:<p>TrkC-IN-1 (Compound 6c) is an inhibitor of TrkC, with IC50 values of 3.3-7.1 and 7.3-10.2 μΜ for EBC-1 and HT-29 cells, respectively. This compound shows potential for research in the field of cancer therapeutics.</p>Fórmula:C28H20BrN5O2Cor e Forma:SolidPeso molecular:538.395FGFR4-IN-4
CAS:<p>FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.</p>Fórmula:C28H32Cl2N6O5Pureza:98%Cor e Forma:SolidPeso molecular:603.5TRK-IN-28
CAS:<p>TRK-IN-28 (compound 30f) functions as a TRK inhibitor, displaying potencies with IC 50 values of 0.55 nM for TRK WT, 25.1 nM for TRK G595R, and 5.4 nM for TRK G667C. Another TRK inhibitor, TRK-IN-2, exhibits antiproliferative effects with IC 50 values against multiple cell lines: 9.5 nM for Ba/F3-ETV6-TRKA WT, 3.7 nM for Ba/F3-ETV6-TRKB WT, 205.0 nM for Ba/F3-LMNA-TRK G595R, and 48.3 nM for Ba/F3-LMNA-TRKA G667C [1].</p>Fórmula:C27H25F2N7Cor e Forma:SolidPeso molecular:485.53DDR1-IN-10
CAS:<p>DDR1-IN-10 (compound 7q) is an inhibitor of DDR1. It is applicable in research related to pancreatic cancer, non-small cell lung cancer, and gastric cancer.</p>Fórmula:C24H25F4N5O2Cor e Forma:SolidPeso molecular:491.481NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C20H16O7Cor e Forma:SolidPeso molecular:368.34EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Fórmula:C33H28N6O3SCor e Forma:SolidPeso molecular:588.68EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Fórmula:C14H11BrN4O2SCor e Forma:SolidPeso molecular:379.23EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Fórmula:C27H31ClN7O3PCor e Forma:SolidPeso molecular:568.01EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Fórmula:C30H35FN6O3Cor e Forma:SolidPeso molecular:546.64TrkA-IN-7
CAS:<p>TrkA-IN-7 (Compound 4) is an inhibitor of tropomyosin receptor kinase A (TrkA), with a Kd value of 40 μM.</p>Fórmula:C16H13N3O3Cor e Forma:SolidPeso molecular:295.293JBJ-02-112-05
CAS:<p>JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].</p>Fórmula:C27H20N4O2SPureza:98%Cor e Forma:SolidPeso molecular:464.54Lucitanib dihydrochloride
CAS:<p>Lucitanib dihydrochloride (E-3810 dihydrochloride) is an efficient VEGFR1-3, FGFR1-3, and PDGFRalpha/β inhibitor, used in metastatic breast cancer research.</p>Fórmula:C26H27Cl2N3O4Cor e Forma:SolidPeso molecular:516.42PET-cGMP
CAS:<p>PET-cGMP is an analogue of cyclic guanosine monophosphate and functions as a potent, selective agonist for PKGI. It exhibits an EC50 of 3.8 nM for PKGIβ and 193 nM for PKGII.</p>Fórmula:C18H16N5O7PCor e Forma:SolidPeso molecular:445.323HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Fórmula:C26H32N8O3Cor e Forma:SolidPeso molecular:504.58AMG-25
CAS:<p>AMG-25 (c-Kit-IN-5-1) is a c-Kit inhibitor that inhibits c-Kit, KDR, p38, Lck, and Src, and can be used for the study of mast cell-associated fibrotic diseases.</p>Fórmula:C23H17N5O2Pureza:98.16%Cor e Forma:SolidPeso molecular:395.41HER2-IN-8
CAS:<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Fórmula:C26H25F2N9O3Cor e Forma:SolidPeso molecular:549.53EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Cor e Forma:SolidPeso molecular:397.424EGFR-IN-38
CAS:<p>EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.</p>Fórmula:C25H24ClN7O2Cor e Forma:SolidPeso molecular:489.96EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Fórmula:C30H26N8OCor e Forma:SolidPeso molecular:514.58EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Fórmula:C31H30FN7OCor e Forma:SolidPeso molecular:535.61HER2-IN-7
CAS:<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Fórmula:C28H26F3N7O3Cor e Forma:SolidPeso molecular:565.55EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Fórmula:C26H27ClN6O2Cor e Forma:SolidPeso molecular:490.98Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Fórmula:C32H31ClN6O4Cor e Forma:SolidPeso molecular:599.08VEGFR2-IN-1
CAS:<p>VEGFR2-IN-1 is a VEGFR2 inhibitor with antitumor activity used in the study of breast cancer.</p>Fórmula:C22H18N6SPureza:98.15%Cor e Forma:SolidPeso molecular:398.48EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Fórmula:C16H16N4O2SCor e Forma:SolidPeso molecular:328.39Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Fórmula:C31H33Cl2FN4O5SCor e Forma:SolidPeso molecular:663.59DDR1-IN-8
CAS:<p>DDR1-IN-8 (compound 7s) is a potent inhibitor of DDR1/2, exhibiting IC50 values of 0.045 μM and 0.126 μM, respectively, and possesses antitumor activity.</p>Fórmula:C23H24F3N5O2Peso molecular:459.46HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Fórmula:C19H14BrF3N2OCor e Forma:SolidPeso molecular:423.23BNN-20
CAS:<p>BNN-20 is a synthetic micro-neurotrophic factor that mimics Brain-Derived Neurotrophic Factor (BDNF) and exhibits region-specific neuroprotective and neurogenesis-promoting effects. It is applicable in research related to Parkinson's disease.</p>Fórmula:C20H30O2Cor e Forma:SolidPeso molecular:302.45EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Fórmula:C12H14N4OS2Cor e Forma:SolidPeso molecular:294.4c-Fms-IN-15
CAS:<p>c-Fms-IN-15 (compound 8g) is a potent inhibitor of FMS kinase, with an IC50 of 563 nM.</p>Fórmula:C29H28F3N7O2Peso molecular:563.57Protein kinase inhibitor 4
CAS:<p>Protein kinase inhibitor 4 (Compound 3) is a chemical that acts as a protein kinase inhibitor, specifically targeting TRK-A with an IC50 of 3.0 nM, and ROS1 with an IC50 of 104 nM.</p>Fórmula:C25H24F2N6O3SPeso molecular:526.56BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Fórmula:C18H15N3O2Cor e Forma:SolidPeso molecular:305.331EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Fórmula:C24H15FO3Cor e Forma:SolidPeso molecular:370.37CL-A3-7
CAS:<p>CL-A3-7 is a viral-cell fusion inhibitor targeting the RSVF protein. It functions by blocking the interaction between the virus and the host's IGF1R, effectively inhibiting the infection of both wild-type and K394R mutant strains of RSV. This compound is suitable for use in antiviral drug development and resistance studies related to RSV.</p>Fórmula:C24H22Br2F2N2O3Cor e Forma:SolidPeso molecular:584.252-Methyl-3-phenylquinoxaline
CAS:<p>2-Methyl-3-phenylquinoxaline (compound 38) serves as an effective inhibitor of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase (PDGF-RTK), exhibiting significant inhibitory activity against the full-length PDGFR kinase in intact cells (IC50 greater than 100 μM).</p>Fórmula:C15H12N2Cor e Forma:SolidPeso molecular:220.27EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Fórmula:C27H25N3O6SCor e Forma:SolidPeso molecular:519.57HER2-IN-12
<p>HER2-IN-12 is an HER2 inhibitor with an IC50 value of 121 nM and can be used to study cancers such as breast cancer.</p>Fórmula:C17H18BrN5O2SCor e Forma:SolidPeso molecular:436.33FGFR-IN-16
CAS:<p>FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, exhibiting IC50 values of 8 nM, 4 nM, and 3.8 nM respectively. It plays a crucial role in cancer research.</p>Fórmula:C30H27Cl2N7O4Cor e Forma:SolidPeso molecular:620.49EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Cor e Forma:SolidG-744
CAS:<p>G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM).</p>Fórmula:C29H29N5O3SPureza:98%Cor e Forma:SolidPeso molecular:527.64TAS05567
CAS:<p>TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM).</p>Fórmula:C21H29N9O2Pureza:98%Cor e Forma:SolidPeso molecular:439.51EGFR-IN-126
CAS:<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Fórmula:C28H28BrFN4O3Cor e Forma:SolidPeso molecular:567.45EGFR-IN-160
CAS:<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Fórmula:C15H12N2O4Cor e Forma:SolidPeso molecular:284.278-Br-cGMP-AM
CAS:<p>8-Br-cGMP-AM, a derivative of 8-Br-cGMP, acts as an activator of PKG (cGMP-dependent protein kinase), inducing various biological effects such as vasodilation and platelet inhibition. This compound is utilized in the research of cardiovascular diseases.</p>Fórmula:C13H15BrN5O9PCor e Forma:SolidPeso molecular:496.16DYRKs-IN-1
CAS:<p>DYRKs-IN-1 has antitumor activity.</p>Fórmula:C30H30ClN7O4Pureza:98%Cor e Forma:SolidPeso molecular:588.06
